国家食品药品监管总局通告9批次药品不合格

2018-02-03 安慧娟 中国医药报

近日,国家食品药品监管总局发布通告,经中国食品药品检定研究院等9家药品检验机构检验,标示为深圳翰宇药业股份有限公司等9家企业生产的9批次药品不合格。

近日,国家食品药品监管总局发布通告,经中国食品药品检定研究院等9家药品检验机构检验,标示为深圳翰宇药业股份有限公司等9家企业生产的9批次药品不合格。

不合格产品的标示生产企业、药品品名和生产批号为:深圳翰宇药业股份有限公司生产的批号为1123161204的注射用生长抑素,长春人民药业集团有限公司生产的批号为20160701的安胃片,哈尔滨大洋制药股份有限公司生产的批号为151202的肝速康胶囊,长春银诺克药业有限公司生产的批号为20160902的降脂宁颗粒,北京同仁堂科技发展股份有限公司制药厂生产的批号为15080858的开胸顺气丸,重庆灵方三帆生物制药有限公司生产的批号为150903的麝香壮骨膏,太康海恩药业有限公司生产的批号为161101的胃蛋白酶颗粒,多多药业有限公司生产的批号为1609231的维生素E烟酸酯胶囊,齐鲁制药有限公司生产的批号为5120108AE的注射用头孢拉定。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1672228, encodeId=eb0b16e222875, content=<a href='/topic/show?id=84848e4625a' target=_blank style='color:#2F92EE;'>#药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87462, encryptionId=84848e4625a, topicName=药品监管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3026899023, createdName=yzh408, createdTime=Wed Dec 26 00:39:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032410, encodeId=5a292032410b5, content=<a href='/topic/show?id=279210098931' target=_blank style='color:#2F92EE;'>#食品药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100989, encryptionId=279210098931, topicName=食品药品监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Feb 06 20:39:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668958, encodeId=e42c1668958de, content=<a href='/topic/show?id=1086203266c' target=_blank style='color:#2F92EE;'>#不合格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20326, encryptionId=1086203266c, topicName=不合格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77c26479803, createdName=echonoir, createdTime=Sat Dec 01 13:39:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371514, encodeId=94e613e151482, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Mon Feb 05 04:39:00 CST 2018, time=2018-02-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1672228, encodeId=eb0b16e222875, content=<a href='/topic/show?id=84848e4625a' target=_blank style='color:#2F92EE;'>#药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87462, encryptionId=84848e4625a, topicName=药品监管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3026899023, createdName=yzh408, createdTime=Wed Dec 26 00:39:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032410, encodeId=5a292032410b5, content=<a href='/topic/show?id=279210098931' target=_blank style='color:#2F92EE;'>#食品药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100989, encryptionId=279210098931, topicName=食品药品监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Feb 06 20:39:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668958, encodeId=e42c1668958de, content=<a href='/topic/show?id=1086203266c' target=_blank style='color:#2F92EE;'>#不合格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20326, encryptionId=1086203266c, topicName=不合格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77c26479803, createdName=echonoir, createdTime=Sat Dec 01 13:39:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371514, encodeId=94e613e151482, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Mon Feb 05 04:39:00 CST 2018, time=2018-02-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1672228, encodeId=eb0b16e222875, content=<a href='/topic/show?id=84848e4625a' target=_blank style='color:#2F92EE;'>#药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87462, encryptionId=84848e4625a, topicName=药品监管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3026899023, createdName=yzh408, createdTime=Wed Dec 26 00:39:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032410, encodeId=5a292032410b5, content=<a href='/topic/show?id=279210098931' target=_blank style='color:#2F92EE;'>#食品药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100989, encryptionId=279210098931, topicName=食品药品监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Feb 06 20:39:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668958, encodeId=e42c1668958de, content=<a href='/topic/show?id=1086203266c' target=_blank style='color:#2F92EE;'>#不合格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20326, encryptionId=1086203266c, topicName=不合格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77c26479803, createdName=echonoir, createdTime=Sat Dec 01 13:39:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371514, encodeId=94e613e151482, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Mon Feb 05 04:39:00 CST 2018, time=2018-02-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1672228, encodeId=eb0b16e222875, content=<a href='/topic/show?id=84848e4625a' target=_blank style='color:#2F92EE;'>#药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87462, encryptionId=84848e4625a, topicName=药品监管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3026899023, createdName=yzh408, createdTime=Wed Dec 26 00:39:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032410, encodeId=5a292032410b5, content=<a href='/topic/show?id=279210098931' target=_blank style='color:#2F92EE;'>#食品药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100989, encryptionId=279210098931, topicName=食品药品监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Feb 06 20:39:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668958, encodeId=e42c1668958de, content=<a href='/topic/show?id=1086203266c' target=_blank style='color:#2F92EE;'>#不合格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20326, encryptionId=1086203266c, topicName=不合格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77c26479803, createdName=echonoir, createdTime=Sat Dec 01 13:39:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371514, encodeId=94e613e151482, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Mon Feb 05 04:39:00 CST 2018, time=2018-02-05, status=1, ipAttribution=)]
    2018-02-05 wwzzly

相关资讯

关于公布2017年度国家自然科学基金申请项目评审结果的通告

2017年3月1日至3月20日项目申请集中接收期间,国家自然科学基金委员会(以下简称自然科学基金委)共接收项目申请190840项,经初步审查和复审后共受理187135项。依据《国家自然科学基金条例》和国家自然科学基金相关管理办法,经专家评审和委务会议审批,决定资助面上项目18136项、重点项目667项、重大项目2项、重点国际(地区)合作研究项目107项、青年科学基金项目17523项、优秀青年科学基

食药监总局责令两药企立即召回红花、喜炎平注射液

因出现严重不良反应,食药监总局责令两药企立即召回红花、喜炎平注射液。

关于征集2017年度地球科学领域重大项目立项建议的通告

为了进一步完善重大项目立项机制,做好项目的立项和资助工作,地球科学部根据国家自然科学基金管理办法的规定,面向科技界征集重大项目立项建议。重大项目要把握科学前沿,根据国家经济、社会、科技发展的需要,重点选择具有战略意义的重大科学问题,组织学科交叉研究和多学科综合研究,进一步提升源头创新能力。一、重大项目定位重大项目面向科学前沿和国家经济、社会、科技发展及国家安全的重大需求中的重大科学问题,超前部署,